Abstract
Objective: The most common recommendation for GnRH antagonists is to initiate treatment after a fixed number of days of FSH administration or when the lead follicle is between 12–14mm in diameter. The purpose of this investigation was to compare our experience with IVF cycles in which a GnRH antagonist was initiated when the lead follicle was greater than 14mm in diameter with those in which the lead follicle was 14mm or less in diameter.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
